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Abstract 
 
Bone with distant metastasis and morbidity due to skeletal complications is a lesion that encouraged many 
authors to focus on the new radiotracers for better diagnosis regarding high sensitivity and specificity. How-
ever, 99mTc-Methylene diphosphonate (MDP) bone scintigraphy (BS) is the current standard imaging due 
to increase adsorption of the tracer at osteoblastic sites; it shows false-positives in degenerative changes and 
false-negatives in bone marrow metastasis. Recently, Prostate Specific Membrane Antigen (PSMA) is the 
promising target in prostate cancer imaging due to the over-expression in cancer cells. 68Ga-PSMA-11, a 
small molecule with PSMA enzyme inhibition activity has benefit in bone and lymph-node recurrences and 
staging. Moreover, as degenerative changes do not have PSMA uptake will have not positive in response to 
therapy, bone scan has enough quality for degenerative changes. With this consideration, BS is unable to 
differentiate bone metastasis from degenerative changes. 68Ga-PSMA-11 could overcome to this limitation 
from conventional imaging as well. Finally, we concluded that PSMA PET-CT would have better sensitivity 
and specificity due to unique distinction for detecting metastases.  
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Introduction 
99mTc-MDP BS is the most common scan for 
detecting bone metastasis with high sensitivity 
(range 62-89%) for bone metastasis in PCa 
[1]. Therefore, guidelines suggest BS to be 
performed in patients with high risk PCa or 
those presenting with bone symptoms [2-4]. 
As bone metastasis firstly commence in bone 
marrow, hence BS not able to detect bone 
marrow lesions or early osteoblastic activity. 
With modern hybrid imaging SPECT-CT 
(Single Photon Emission Computed 
Tomography Computed Tomography), MDP 
BS able to correctly characterized planner 
imaging equivocal lesions [5]. Despite  these  
limitations,  bone  scan  preferred  as standard  
scan for  bone metastasis  in  clinical  
diagnosis of prostate cancer. 18F-Fluoride 
PET [6] is superior to BS for detection of bone 
metastasis due to the prostate cancer but it did 
not routinely perform in clinical practice. 
These days prostate-specific membrane 
antigen (PSMA) has been a promising tracer 
in low and high grade of PCa. Regarding to its 
high expression in PCa cells [7], it used as a 
biomarker like gleason score for evaluation of 
metastasis and progression [8]. Meanwhile, 
small molecule inhibitors have been 
developed to target PSMA; Glu-NH-CO-NH-
Lys-(Axe)-[68Ga (HBED-CC)] (68Ga-PSMA
-11) is the   most investigated ligand which 
has high clinical  value  for  lymph  node  
staging [9]  and  detection  of  local recurrence 
[10, 11].  
68Ga-PSMA-11 PET-CT  2019. The Cancer Press,1:68-74                                                                                                             69 
Vol. 1, Mar. 2019 
References 
 
6. Even-Sapir E, Metser U, Mishani E, Lerman H, Lievssitz G, et al. (2006). The detection of bone metastases in patients 
with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-
fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287-97. 
7. Silver  DA,  Pellicer  I,  Fair  WR,  Heston  WD,  Cordon-Cardo  C  (1997) Prostate-specific membrane antigen 
expression in normal and malignant human tissues. Clin Cancer Res 3: 81-5. 
8. Chang  SS  (2004)  Overview  of  prostate-specific  membrane  antigen.  Rev Urol 6: S13-S18. 
9. Gupta  M,  Choudhury  PS,  Hazarika  D,  Rawal  S  (2017)  A  Comparative study   of   68Gallium-prostate   Specific   
membrane   antigen   positron emission  tomography-computed  tomography  and  magnetic  resonance imaging for 
lymph node staging in high risk prostate cancer patients: An initial experience. World J Nucl Med 16: 186-191. 
10. Eiber  M,  Maurer  T,  Souvatzoglou  M,  Beer  AJ,  Wester  HJ,  et  al.(2015) Evaluation  of  Hybrid  68Ga-PSMA  
Ligand  PET/CT  in  248  Patients  with Biochemical  Recurrence  After  Radical  Prostatectomy.  J  Nucl  Med  56:668-
674. 
11. Perera  M,  Papa  N,  Christidis  D,  Hofman  MS,  Bolton  D,  et  al.  (2016) Sensitivity,  specificity,  and  predictors  
of  positive  68Ga-prostate-specific membrane  antigen  positron  emission  tomography  in  advanced  prostate cancer: A 
systematic review and meta-analysis. Eur Urol 70: 926-937. 
12. Pyka  T,  Okamoto  S,  Dahlbender  M,  Heck  M,  Eiber  M,  et  al.  (2016) Comparison  of  bone  scintigraphy  and  
68Ga-PSMA  PET  for  skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43: 2114-2121. 
13. Schreiter  V,  Gericke  M,  Heimann  U,  Steffen  I,  Hamm  B,  et  al.  (2016) Comparison  of  [68Ga]Ga-PSMA-
HBED-CC  PET  versus  whole-body bone  scintigraphy  for  the  detection  of  bone  metastases  in  patients  with 
prostate cancer. J Nucl Med Radiat Ther 7: 302. 
14. Lengana  T,  Modiselle  M,  Lawal  I,  Ebenhan  T,  Vorster  M,  et  al.  (2017) 68Ga-PSMA-PET/CT and bone 
scintigraphy imaging for staging of high- risk prostate cancer. J Nucl Med 58: 757. 
www.imaqpress.com  
www.thecancerpress.com 
PSMA PET is very sensitive for high grade 
prostate cancer cells as well as low levels but BS 
seems to be sensitive for high grades and is 
controversial for low level of PSA [12, 13]. In 
short, PSMA-PET has shown higher sensitivity 
and specificity than BS (90.5% vs. 73.68%, and 
97.0% vs. 86%) for bone metastasis of prostate 
cancer [14].   
Case report 
69 Years male with adenocarcinoma prostate, PSA 
115 ng/ml enrolled in our center for more 
evaluation of prostate cancer metastasis. After IV 
injection of 20mci of 99mTC-MDP scanning was 
performed three hours later in multiple spot views.  
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The scan showed abnormally increased 
inhomogeneous uptake in lumbar spine. No other 
abnormal uptake was noted in the rest of the 
skeleton. In short, bony lesion with osteoblastic 
reaction of lumbar vertebrae is involved. 
Moreover, SPECT imaging was performed from 
thoracolumbar spine and reconstruction was 
performed in the transverse, coronal and sagital 
axes. The SPECT slices showed abnormal uptake 
in body of lumbar vertebrae. For more assessment 
MRI correlation for ruling out of metastasis and 
degenerative change was recommended.  
After bone SPECT, the patient refers to the 68Ga-
PSMA PET-CT for better diagnosis. In this 
reason, therefore, 4.4 mCi of 68Ga-PSMA-11 was 
administered intravenously via the vein in the 
dorsum of the left hand. To allow for distribution 
and uptake of radiotracer, the patient was allowed 
to rest quietly for 60 minutes in a shielded room. 
Imaging was performed on an integrated 6-slice 
PET/CT scanner, with scanning from the skull top 
to the mid thigh. CT scanning was performed 
without oral or intravenous contrast material. 
There are PSMA uptakes in the peri-vascular, sub 
carina and right hilar lymph node with SUVmax 
up to 17.71. There are numerous nodal abnormal 
uptakes in the para-aortic and pelvic chains with 
SUVmax up to 40.16. In addition the scan showed 
PSMA uptake in the peripheral of the liver. 
Moreover, Physiologic tracer uptake was seen 
throughout spleen, small intestine and urinary 
bladder. Intense PSMA uptake at prostate gland 
with SUVmax 27.20 was seen. Numerous 
Osteoblastic bone metastasis throughout the axial 
and appendicualr skeleton including spine, ribs 
bilaterally sternum, scapulae, clavicle, humera, 
pelvic and proximal both femura.  
Regarding patient’s history, PSMA activity at 
prostate gland as a primary tumor, multiple para-
aortic and pelvic chain lymph nodes metastasis, 
liver metastasis and wide spread bone metastasis 
as mentioned above.  
Result and Conclusion 
For the current patient, as discussed above, bone 
scan and 68Ga-PSMA PET were performed 
between one week distances. Bone scan showed 
one lesion in lumbar spine while PET scan 
revealed multiple bone metastases Therefore, in 
this case disseminated and/or refractory to 
treatment, RIT with 177Lu-PSMA is 
recommended. While 99mTc-MDP BS is the 
current standard imaging for bone metastasis of 
prostate cancer but it seems that PSMA PET is 
superior to BS for metastatic work up in high risk 
prostate cancer [Figures 1-3 section A, B].  
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FIG1. a) After IV injection of 20mci of 99mTC-MDP scanning was performed 3 hours later in 
multiple spot views. The scan showed abnormally increased inhomogeneous uptake in lumbar spine. 
No other abnormal uptake was noted in the rest of the skeleton. b) SPECT imaging was performed 
from thoracolumbar spine and reconstruction was performed in the transverse, coronal and sagital 
axes. The SPECT slices showed abnormal uptake in body of lumbar vertebrae. 
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FIG2. B) 68Ga-PSMA-11 PET-CT scan 
FIG3. 68Ga-PSMA PET/CT scan, Skull top to Mid-Thigh 
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Moreover, as degenerative changes do not have PSMA uptake will have not positive in 
response to therapy, bone scan has enough quality for degenerative changes. With this 
consideration, BS is unable to differentiate bone metastasis from degenerative changes. In 
addition, we believe that PSMA PET will have upper hand in degenerative changes versus 
bone scan.  
